Archive for the ‘Uncategorized’ Category

Sharp Rise in Lyme Cases Due to Change in How They Are Reported

https://www.lymedisease.org/sharp-rise-in-lyme-cases/

Sharp Rise in Lyme Cases Due to Change in How They Are Reported

Reported Lyme disease cases in the U.S. rose nearly 70% in 2022. The CDC says it’s not because of a large increase of new infections, but rather because of a change in reporting requirements.

According to the CDC, there were more than 62,000 reported cases in 2022. This was up from about 37,000 a year from 2017 through 2019.

Although the CDC estimates that about half a million people get Lyme disease in the US every year, “reported cases” are those which follow a strict case definition and specialized requirements.

In the past, in order for a Lyme case to be officially counted, local health departments needed to go through a complicated verification process for each case. In 2022, reporting requirements were eased in states the CDC considers “high incidence.” In those states, Lyme cases are now counted based solely on a positive Lyme test.

Read more here:

Centers for Disease Control and Prevention

CNN

______________

**Comment**

Ha, ha, ha….this is a joke.

The chance of getting a positive test is akin to winning the lottery, so numbers in reality are exponentially higher yet.

For more:

It’s important to clearly understand that government sanctioned Lyme testing (like COVID testing) is utterly useless:

 

 

Statement From the Physicians Committee on Neuralink’s Purported Patient Implant

Go here to see the eerie and creepy Dawn of Augmented Humanity which exposes Neuralink’s CIA and military roots to it’s developers, whose shocking admissions should cause us all to pause. It all comes back to Harvard scientist, Dr. Lieber’s work, who was found guilty of hiding financial ties to China from federal agencies.  

https://www.pcrm.org/news/news-releases/statement-physicians-committee-neuralinks-purported-patient-implant

Statement from the Physicians Committee on Neuralink’s Purported Patient Implant

surgery simulation
Photo: Getty Images

On January 29, 2024, Elon Musk claimed on his social media platform X that a patient had received an implant from Musk’s brain-computer interface company Neuralink “and is recovering well.” The statement has not been independently verified. It is important to remember that Musk has a long track record of misleading the public about Neuralink’s supposed developments. In addition, Neuralink has a well-documented history of conducting unnecessary, sloppy experiments in monkeys, pigs, sheep, and other animals that raise serious concerns about the safety of its device. Past experiments revealed serious safety concerns stemming from the device’s invasiveness and rushed actions by company employees. In addition, a significant number of medical devices approved for clinical trials fail to ever make it to the market. As such, the public should continue to be skeptical of the safety and functionality of any device produced by Neuralink.

According to a March 2023 news report, which cited Neuralink employees, the U.S. Food and Drug Administration (FDA) itself “raised safety concerns” related to “device’s lithium battery; the potential for the implant’s tiny wires to migrate to other areas of the brain; and questions over whether and how the device can be removed without damaging brain tissue.”

In addition, Musk’s true intentions for Neuralink are disturbingly clear. He has repeatedly said the goal of the company is “to achieve a symbiosis with artificial intelligence,” which is not necessarily in line with developing treatments for patients.

The Physicians Committee continues to urge Elon Musk and Neuralink to shift to developing a noninvasive brain-computer interface. Researchers elsewhere have already made progress to improve patient health using such noninvasive methods, which do not come with the risk of surgical complications, infections, or additional operations to repair malfunctioning implants. Noninvasive devices are already demonstrating the ability to improve quality of life for older adults and elderly patients, translate brain activity into intelligible speech, and assist paralyzed patients(See link for article)

_____________

**Comment**

The article has a timeline of the controversy surrounding the more than 1,500 monkeys Neuralink had killed in experiments involving the brain-computer interface, and yet in May 2023, the FDA approved Neuralink’s request for permission to pursue human trials!

Buyer Beware!

For more:

Medical Gaslighting and Lyme Disease: The Patient Experience

healthcare-12-00078

Medical Gaslighting and Lyme Disease: The Patient Experience

Jennifer L. Fagen 1, *, Jeremy A. Shelton 2 and Jenna Luché-Thayer 3

Abstract:

Even though there are approximately half a million new cases of Lyme disease in the US annually, according to the CDC, it is often undiagnosed or misdiagnosed, which can result in a chronic, multisystemic condition. Lyme disease is a recognized public health threat and is a designated “notifiable disease”. As such, Lyme disease is mandated to be reported by the CDC. Despite this, both acute and chronic Lyme disease (CLD) have been relegated to the category of “contested illnesses”, which can lead to medical gaslighting. By analyzing results from an online survey of respondents with Lyme disease (n = 986), we elucidate the lived experiences of people who have been pushed to the margins of the medical system by having their symptoms attributed to mental illness, anxiety, stress, and aging. Further, respondents have had their blood tests and erythema migrans (EM) rashes discounted and were told that CLD simply does not exist. As a result, a series of fruitless consultations often result in the delay of a correct diagnosis, which has deleterious consequences. This is the first study that addresses an extensive range of gaslighting techniques experienced by this patient population.

(See top link for entire paper)

_____________

For more:

Review: Borrelia Miyamotoi

https://danielcameronmd.com/review-borrelia-miyamotoi/

REVIEW: BORRELIA MIYAMOTOI

borrelia-miyamotoi

Borrelia miyamotoi is an emerging tick-borne illness that is transmitted by the deer tick. The most common symptoms of a B. miyamotoi infection include fever, fatigue, headache, chills, myalgia, arthralgia, and nausea.

In their article, “Human Borrelia miyamotoi Infection in North America,” Burde and colleagues discuss the frequency and location of infection in ticks and people, clinical presentation and complications, diagnosis, treatment, and prevention.

Prevalence of B. miyamotoi

B. miyamotoi-infected ticks have been reported throughout the northeastern, northern Midwestern, and western United States. They’ve also been detected in all Canadian provinces except Newfoundland and Labrador.

The prevalence of Borrelia miyamotoi infections is difficult to determine, since the illness is not nationally reportable in the U.S. but reportable in only a few states including Connecticut, Maine, Massachusetts, Minnesota, New Jersey, Vermont, and Wisconsin. And, confirmation of the diagnosis depends upon laboratory testing, which is not always available.

Furthermore, diagnosis can be challenging. “The discrepancy between diagnosed and undiagnosed infection is probably even greater for B. miyamotoi, a tick-borne disease that lacks an easily identifiable clinical marker, such as the erythema migrans rash, and is less well known by health care workers and the general public,” the authors write.

Transmission

B. miyamotoi can be transmitted to humans through the bite of an infected black-legged (deer) tick. Several studies have found that it may be transmitted through blood transfusions, as well.

The B. miyamotoi pathogen can be transmitted from an infected female tick to her eggs, which may result in some larval ticks harboring the infection and transmitting it to a host. “Other larvae become infected after taking a blood meal on an infected mouse reservoir host, molt to the nymphal stage, and then transmit infection to another mouse or human,” they write.

Symptoms & Treatment

B. miyamotoi symptoms can be non-specific and an individual may appear to have a viral-like illness with fever, chills, headache, myalgia, fatigue, arthralgia, and gastrointestinal complaints, according to the authors.

“The most striking clinical feature of B. miyamotoi is relapsing fever with an initial febrile episode followed by a period of wellness and then one or more additional febrile episodes,” the authors write.

Some studies have found that the “average time between relapses was 9 days with a range of 2 days to 2 weeks.”

However, not all individuals develop relapsing fever. “In the largest case series of B. miyamotoi cases in the US, only 2 of 51 cases (4%) developed relapsing fever.”

READ: Don’t Rely on Relapsing Fever to Diagnose B. miyamotoi 

Treatment of B. miyamotoi disease typically involves using the same antibiotics to treat Lyme disease: doxycycline, tetracycline, erythromycin, penicillin, and ceftriaxone. However, there have been no trials to evaluate the effectiveness of these treatments.

Co-infections worsen disease

Co-infections can worsen the illness. There have been reported cases of B. miyamotoi co-infection with B. burgdorferi and/or Babesia microti.

“Previous studies have found that coinfection of B. burgdorferi with either Babesia microti or with Anaplasma phagocytophilum are often associated with more severe disease compared with that caused by B. burgdorferi infection alone,” the authors write.

Testing for the infection can include blood smear, polymerase chain reaction (PCR), and/or antibody detection.

Authors’ Conclude:

“The possibility of B. miyamotoi infection should be considered in any patient with a febrile illness who resides in or has recently traveled to a region where Lyme disease is endemic, especially during the late spring, summer, or early fall.”

References:
  1. Burde J, Bloch EM, Kelly JR, Krause PJ. Human Borrelia miyamotoi Infection in North America. Pathogens. 2023 Apr 3;12(4):553. doi: 10.3390/pathogens12040553. PMID: 37111439; PMCID: PMC10145171.

_______________

For more:

Since Borrelia miyamotoi is not a reportable illness to the CDC, no one has any clue about prevalence but reports are coming in continually that it’s highly likely to be a much bigger problem than ‘authorities’ believe.
It was recently discovered that:

Also, Borrelia miyamotoi has been in California ticks for a long time:

https://madisonarealymesupportgroup.com/2018/02/15/b-miyamotoi-in-ca-ticks-for-a-long-time/

The following case shows how you can become infected while traveling:  https://madisonarealymesupportgroup.com/2020/10/24/a-case-of-borrelia-miyamotoi/

New Wave of Frankinfoods Coming to a Store Near You

https://anh-usa.org/new-wave-of-frankenfoods-coming-to-a-store-near-you/  (Go here to send a message to your reps)

New Wave of Frankenfoods, Coming to a Store Near You

New Wave of Frankenfoods, Coming to a Store Near You

The government is making decisions about genome-edited food that prevent consumers from identifying it, exposing us to potential risks. Action Alert!

Did you know that meat from a genome-edited (GE) cow could soon be in grocery stores, and it wouldn’t be distinguishable from other meat? That’s because it will likely not need to be labeled as being GE (or “bioengineered” to use the USDA’s term). Worse, the FDA has cleared this product with only cursory oversight because it believes the GE cows to be “low-risk.”

This is a betrayal of consumers’ right to know about the contents and origins of their food and a failure to adequately protect public health. If you’re like us, you’d want an abundance of evidence showing that the safety profile of GE and non-GE meat were equivalent before they were freely sold to the public without any labeling to separate them. We’d also want plenty of studies verifying long-term safety. Unfortunately this is not the approach taken by the federal government.

The only thing that we know can stop the FDA continuing on its mistaken path which assumes bioequivalence of GE and non-GE food is “us.” The great us: the American public. We have to fight back and call for more stringent oversight of GE food.

Speeding up approvals for industry’s sake

Last year, the FDA cleared meat from GE cattle to enter the marketplace. It was the fourth approval of a GE animal in the past three years, a significant uptick compared to three approvals in the prior 11 years.

This accelerated pace looks, to us, like a clear signal that the FDA wants to serve the interests of Big Ag and Big Biotech, not the public. Last year, these special interests complained in a letter to USDA Secretary Tom Vilsack that the FDA was taking too long to approve GE animals, arguing for the USDA to take over their regulation. You can see why: the USDA approved dozens of GE plants for cultivation since the mid-1990s; in 2020, the agency even released a rule that exempted many GE crops from review.

Race to the bottom

The FDA apparently doesn’t want to be outdone by the USDA in its willingness to kowtow to industry. By categorizing GE cattle as “low-risk,” the agency has made it easier for food and other products from those cattle to come to market.

The FDA views intentional changes to an animal’s DNA as an animal drug falling under the FDA’s jurisdiction. As such, companies producing GE animals are generally subject to premarket requirements like an approved new animal drug application (NADA). Except, as explained in an FDA guidance document, if the agency decides to skip these requirements because it believes the GE animal in question to be “low-risk.”

The first approved NADA for a food-producing animal was in 2015 with the AquaAdvantage Salmon. In 2020, the agency approved a GE pig both as a food and a drug (the pigs are GE so they do not produce alpha-gal sugars which is responsible for a rare allergy). Before then, GE goatschickens, and rabbits had also been approved, but not for food; these animals are engineered to produce drugs. For example, the GE goats produce a protein in their milk intended to be used for anticlotting treatment in humans.

In 2022, the FDA cleared cattle that are modified to have short, slick hair coats so they can better withstand hot weather. This was the first time the FDA decided to exempt a GE animal from premarket requirements because it was deemed “low-risk.” Why? Because, the agency explains, the genetic change is “equivalent to naturally occurring mutations that have arisen in several breeds of cattle as an adaptation” to tropical weather. In its press release, the agency boasts that the decision:

…demonstrates our ability to identify low-risk [genetic alterations] that don’t raise concerns about safety, when used for food production. We expect that our decision will encourage other developers to bring animal biotechnology products forward for the FDA’s risk determination in this rapidly developing field, paving the way for animals containing low-risk [genetic alterations] to more efficiently reach the marketplace [emphasis added].

That’s right: the FDA is bragging to industry about its lax enforcement of GE animals so these products can more quickly reach a store near you. It’s a signal to industry to prepare to bring more GE food animals before the FDA so they can be rubber-stamped through the process.

Consumers left in the dark

The approval of GE cattle also highlights how the GMO labeling law passed by Congress in 2016 completely sold out on consumersIt’s very likely that meat from the GE cattle will not have to be labeled. Among the many problems with the law that we laid out in our coverage was the very definition of a “bioengineered” food, which excludes many foods developed through genome-editing techniques like CRISPR. The government has taken the position that genome-editing largely produces results that could have been obtained through conventional breeding, so we need not worry about the process used to arrive at that genetic alteration. It’s the final product, rather than the process, that matters to the government.

For example, the USDA decided that a CRISPR-created non-browning mushroom did not have to be regulated nor, by extension, labeled as genetically modified. For the same reason, the GE cattle recently cleared by the FDA will likely not have to be labeled because the modification could in theory be obtained through conventional cattle breeding. As a result, such GE foods aren’t even considered to be GE foods for the purposes of the federal labeling law. Work that one out!

The point is that the government passed a labeling law that does not apply to a huge swath of GE foods. CRISPR and other biotech, nano-science techniques are widely regarded as the future for agriculture, medicine and science more generally, with some observers noting that “with new gene editing techniques, [GMOs] will no longer be necessary.” No wonder Big Biotech lobbyists didn’t work to successfully block the 2016 sham labeling bill – they knew exactly what was in the pipeline.

A broken system

All of this is illustrative of the larger problem that sits within the federal government’s approach to GE products. The entire federal framework for dealing with GE foods focuses on the final product rather than the process used to develop that product. This approach is fundamentally flawed because the processes themselves, like CRISPR gene editing, can produce unpredictable and unintended consequences. Natural genes can be deleted or permanently turned on or off, while hundreds of other genes may change their behavior because of the new insertions or deletions. Even the inserted gene can be damaged or rearranged, and may create proteins that can trigger allergies or promote disease.recent study involving human embryos found that when CRISPR was used to repair a mutation that can cause hereditary blindness, it appeared to “wreak genetic havoc in about half the specimens that the researchers examined.”

Claiming that a specific intended gene alteration can be achieved through natural means as proof that a CRISPR technique targeting this same gene is scientific and legal nonsense. The government has largely absolved itself from looking closely at the potential disasters that are possible when developing and producing GE foods—benefitting the special interests behind GE foods, to the cost of consumers.

GE food dangers

We’ve articulated our opposition to GE foods for many years. Manipulating one or two genes does not just produce one or two desired traits—a single change at the level of DNA has the potential to alter the entire DNA blueprint and numerous other characteristics of the genome-edited organism. This may happen in unexpected and undesirable ways, and these traits can be passed down through generations. Despite the lack of research funding, a substantial body of scientific work has already shown a variety of negative health outcomes from consuming GE foods, such as impaired liver and kidney function, infertility, impaired embryonic development, allergic reactions, damage to the gastrointestinal tract, and more. An increasing abundance of GE animals in the marketplace, indistinguishable from those from animals with unedited genes,  opens the floodgates to even more unintended consequences and potential public health disasters.

The bottom line is that we need proper transparency and oversight over GE foods so we know they’re safe, but the FDA appears to be moving in the opposite direction to appease Big Food and Big Biotech. We must push back to register consumer outrage at this cronyism.

Action Alert! Write to the FDA and Congress, telling them that we need proper oversight over foods from GE animals. Please send your message immediately. (Go to top link to send a message to your reps.)

______________

**Comment**

This is a big deal and requires our participation to stop this madness. Never forget: food is medicine.

Because of the negative connotation of “Frankinfood,” the USDA has relabeled “GMO” to the more acceptable term of “bioengineered,” but do not be fooled: this technology is dangerous.  Even the European Union has ruled that CRISPR plants are GMO’s and should be subjected to the same rules, which unfortunately is not the case in the US.

A recent study has revealed that a new gene editing technology called CRISPR is being used on chickens to enhance their resistance to the bird flu (avian influenza). Researchers are attempting the CRISPR technique to contain the virus genetically.

It must be mentioned here that the “deadly” H1N1 Swine Flu or avian flu was a scam yet declared a Level-6 ‘pandemic’ based on 20 cases (after the corrupt WHO changed the definition of pandemic it to make it fit). Then the CDC lied by stating there were 22 Million cases when they scandalously stopped counting!  Similarly to COVID, the entire saga was used to push a dangerous vaccine which in this case has been linked to narcolepsy, cataplexy and brain damage. You see, this has all been done before.

Animals are being injected with mRNA technology (GMO) but hardly anyone knows about it. In China they are also injecting it into vegetables.
Go here to read about CRISPR & learn that many experts are concerned that genetically modified organisms could be easily weaponized.

Despite the glaring risks of potentially causing hundreds of unintended DNA alterations, GMO products are all the rage in research, because of the top-down approach & monopolization of medicine by dangling carrots for research grants by a corrupt government with a dark agenda. Even medical journals are corrupted by this as well as clinical trials due to an an unholy alliance with Industrygovernment, and University research facilities Besides being unethical, which should be troublesome on its own, science has been replaced by narrative.

CRISPR entails the use of a molecular tool that allows scientists to make targeted edits within DNA. After CRISPR was performed within the study, the scientists then gene edited chickens that were nasally infected with a drastically amplified flu dosage.

While samples taken from the infected chickens showed the gene-editing was successful, it also showed that the process quickly caused several mutations, which means that scientists still have to address the possibility that further evolution of the virus could still occur, and make a bird flu epidemic worse.

As reported by The New York Times, Wendy Barclay, a virologist at Imperial College London and an author of the study, commented on this at a news briefing, saying, “The research is ‘proof of concept that we can move toward making chickens resistant to the virus. But we’re not there yet.’”

It appears none of these researchers are looking into safety.

Sound familiar yet?